You should not take Reclast if you're on Zometa® (zoledronic acid) Injection because it contains the same active ingredient. Additionally, you should not take Reclast if you are pregnant, plan to ...

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Avenacy, a specialty pharmaceutical company focused on supplying critical injectable medications, today announced it has launched Zoledronic Acid Injection, USP in ...

The U.S. Food and Drug Administration (FDA) has approved Reclast® (zoledronic acid) Injection, the first and only once-yearly treatment for postmenopausal osteoporosis. Approximately 8 million women ...

Novartis Pharmaceuticals Corp. in East Hanover, an affiliate of Novartis AG, says it has received approval from the Food and Drug Administration for zoledronic acid (Reclast) injection as a ...

Randomized phase II study of epirubicin (E) plus cyclophosphamide (C) vs. weekly paclitaxel (P) as primary systemic therapy (PST) in patients (pts) with stage II and III breast cancer (BC) ...

Reclast (zoledronic acid or zoledronate) is approved by the Food and Drug Administration (FDA) to treat and prevent osteoporosis in males, females after menopause, and people taking glucocorticoids.

Zoledronic acid injection is indicated for the treatment of hypercalcemia of malignancy and for the treatment of multiple myeloma and bone metastases of solid tumors, in conjunction with standard ...

One annual infusion of zoledronic acid (Reclast) significantly reduces fracture risk in postmenopausal women with osteoporosis, according to results of a major trial. An international group of ...

Zoledronic acid is a potent, new-generation bisphosphonate indicated for the treatment of documented bone metastasis in patients with solid tumors and bone lesions associated with multiple myeloma.